Neptune Technologies & Bioressources Obtains New Patent Directed to Compositions of Omega-3 Fatty Acid Phospholipids Includin...
October 05 2011 - 7:00AM
Neptune Technologies and Bioressources Inc. (Nasdaq:NEPT)
(TSX-V:NTB), announces that the U.S. Patent and Trademark Office
("USPTO") has granted Neptune a new patent covering omega-3
phospholipids comprising polyunsaturated fatty acids, one of the
main bioactive ingredients in all recognized Krill Oils. The patent
is granted for the U.S. market and is valid until 2025.
Neptune's recently issued U.S. patent (U.S. No. 8,030,348)
covers, regardless of the extraction process, novel omega-3 fatty
acid phospholipid compositions suitable for human consumption,
synthetic and/or natural, including compositions extracted from
marine and aquatic biomasses. The 8,030,348 patent protects Neptune
Krill Oil (NKO®) and also covers amongst others, oils and powders
extracted from krill, containing marine phospholipids bonded to EPA
and/or DHA, distributed and/or sold in the U.S. market.
"The U.S. patent confirms Neptune's position as the pioneer in
the marine oil industry, especially in the krill oil business,"
stated Dr. Tina Sampalis, Neptune's Chief Scientific Officer. "This
patent also benefits our majority-owned subsidiaries Acasti Pharma
and NeuroBioPharm as it protects the platform for our
pharmaceutical products. The issuance of this patent expands
Neptune's leadership role in the phospholipid-based nutraceutical
and pharmaceutical markets and represents a significant milestone
by further strengthening the company's intellectual property
portfolio," she added.
Mr. Henri Harland, Neptune's President and Chief Executive
Officer, also indicated that:
- Intellectual property is a very important and strategic asset
for Neptune and our three distinct families of patents and pending
applications in more than 30 countries demonstrate that.
- Neptune has retained the services of one of the leading lawyer
firms to diligently prepare the files to obtain a solid and robust
patent, which was achieved.
- We expect a strong reaction from the competition as this new
patent implies that they will not be authorized to distribute
and/or sell any Krill Oil with the above mentioned composition in
the U.S., unless they reach an agreement with Neptune.
He concluded that "It is also the management's obligation to
protect and defend Neptune's assets, in order to maximize
shareholder's value; we intend to fully enforce our patent against
anyone who infringes."
About Neptune Technologies & Bioressources
Inc.
Neptune is an industry-recognized leader in the innovation,
production and formulation of science-based and clinically proven
novel phospholipid products for the nutraceutical and
pharmaceutical markets. The Company focuses on growing consumer
health markets including cardiovascular, inflammatory and
neurological diseases driven by consumers taking a more proactive
approach to managing health and preventing disease. The Company
sponsors clinical trials aimed to demonstrate its product health
benefits and to obtain regulatory approval for label health claims.
Neptune is continuously expanding its intellectual property
portfolio as well as clinical studies and regulatory approvals.
Neptune's products are marketed and distributed in over 20
countries worldwide.
About Acasti Pharma Inc.
Acasti Pharma (TSX-V:APO) is developing a product portfolio of
proprietary novel long-chain omega-3 phospholipids. Phospholipids
are the major component of cell membranes and are essential for all
vital cell processes. They are one of the principal constituents of
High Density Lipoprotein (good cholesterol) and, as such, play an
important role in modulating cholesterol efflux. Acasti Pharma's
proprietary novel phospholipids carry and functionalize the
polyunsaturated omega-3 fatty acids EPA and DHA, which have been
shown to have substantial health benefits and which are stabilized
by astaxanthin, a potent antioxidant. Acasti Pharma is focusing
initially on treatments for chronic cardiovascular and
cardiometabolic conditions within the over-the-counter, medical
food and prescription drug markets.
About NeuroBioPharm Inc.
NeuroBioPharm is pursuing pharmaceutical neurological
applications, and a clinical study for a medical food product with
a multinational partner is already initiated. The development of a
prescription drug candidate is currently in progress. Advanced
clinical development and commercialization is planned to be carried
out with multinational partners.
"Neither Nasdaq nor the TSX Venture
Exchange nor its Regulation Services Provider (as that term is
defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release."
Statements in this press release that
are not statements of historical or current fact constitute
"forward-looking statements" within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995 and Canadian securities
laws. Such forward-looking statements involve known and unknown
risks, uncertainties, and other unknown factors that could cause
the actual results of the Company to be materially different from
historical results or from any future results expressed or implied
by such forward-looking statements. In addition to statements which
explicitly describe such risks and uncertainties, readers are
urged to consider statements labeled with the terms "believes,"
"belief," "expects," "intends," "anticipates," "will," or
"plans" to be uncertain and forward-looking. The forward-looking
statements contained herein are also subject generally to other
risks and uncertainties that are described from time to time in the
Company's reports filed with the Securities and Exchange Commission
and the Canadian securities commissions.
CONTACT: Neptune Contact:
Neptune Technologies & Bioressources Inc.
Andre Godin, CFO
+1.450.687.2262
a.godin@neptunebiotech.com
www.neptunebiotech.com
CEOcast Contact:
Dan Schustack
+1 212-732-4300
dschustack@ceocast.com
www.ceocast.com
Howard Group Contact:
Dave Burwell
(888) 221-0915
dabe@howardgroupinc.com
www.howardgroupinc.com
New Tymbal Resources (TSXV:NTB)
Historical Stock Chart
From Jun 2024 to Jul 2024
New Tymbal Resources (TSXV:NTB)
Historical Stock Chart
From Jul 2023 to Jul 2024